EI
CTIC

EAM Investors’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

EAM Investors’s Portfolio CTIC Stock Details CTIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-470,576
Closed -$2.74M – 378
2022
Q3 		$2.74M Sell
470,576
-371,173
-44% -$2.31M 0.6% 44
2022
Q2 		$5.03M Sell
841,749
-170,186
-17% -$871K 1.23% 3
2022
Q1 		$4.73M Buy
+1,011,935
New +$3.02M 0.88% 5
2021
Q1 		– Sell
-240,108
Closed -$773K – 485
2020
Q4 		$773K Buy
+240,108
New +$799K 0.13% 288

Other funds holding CTIC

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

EAM Investors's CTIC Position: Q4 2022 in Review

EAM Investors sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q4 2022, closing a stake of 470,576 shares — an estimated $2.74M sold.

EAM Investors first reported a position in CTIC in Q4 2020 and held it in 4 quarters. The position peaked at $5.03M in Q2 2022. 145 funds tracked by Wall St. Rank hold CTIC as of Q4 2022.

  • EAM Investors reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q4 2022 after selling out during the quarter.
  • EAM Investors sold 470,576 CTI BioPharma Corp. (DE) Common Stock shares in Q4 2022, an estimated $2.74M.
  • EAM Investors first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2020 and held it in 4 quarters.
  • EAM Investors's CTI BioPharma Corp. (DE) Common Stock position peaked at $5.03M in Q2 2022.
  • 145 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q4 2022.

Based on EAM Investors's 13F filing for Q4 2022, filed 14 Feb 2023.